A Study of MabThera (Rituximab) in Patients With Idiopathic Thrombocytopenic Purpura.

NCT00475423 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

122

Enrollment

INDUSTRY

Sponsor class

Conditions

Idiopathic Thrombocytopenic Purpura

Interventions

DRUG: rituximab [MabThera/Rituxan]

Sponsor

Hoffmann-La Roche